Placebo analgesia in chronic pain is a widely studied clinical phenomenon, where expectations about the effectiveness of a treatment can result in substantial pain relief when using an inert treatment agent. While placebos offer an opportunity for non-pharmacological treatment in chronic pain, not everyone demonstrates an analgesic response. Prior research has identified biopsychosocial factors that determine the likelihood of an individual to respond to a placebo, yet generalizability and ecological validity in those studies have been limited due to the inability to account for dynamic personal and treatment effects -- which are well-known to play a role. Here, we assessed the potential of using fine-tuned large language models (LLMs) to predict placebo responders in chronic low-back pain using contextual features extracted from patient interviews, as they speak about their lifestyle, pain, and treatment history. We re-analyzed data from two clinical trials where individuals performed open-ended interviews and used these to develop a predictive model of placebo response. Our findings demonstrate that semantic features extracted with LLMs accurately predicted placebo responders, achieving a classification accuracy of 74% in unseen data, and validating with 70% accuracy in an independent cohort. Further, LLMs eliminated the need for pre-selecting search terms or to use dictionary approaches, enabling a fully data-driven approach. This LLM method further provided interpretable insights into psychosocial factors underlying placebo responses, highlighting nuanced linguistic patterns linked to responder status, which tap into semantic dimensions such as "anxiety," "resignation," and "hope." These findings expand on prior research by integrating state-of-art NLP techniques to address limitations in interpretability and context sensitivity of standard methods like bag-of-words and dictionary-based approaches. This method highlights the role of language models to link language and psychological states, paving the way for a deeper yet quantitative exploration of biopsychosocial phenomena, and to understand how they relate to treatment outcomes, including placebo.

The authors have declared no competing interest.

NCT02013427

This work was supported by National Institutes of Health grant R01AR074274 to Apkarian and by Portuguese national funds through the Foundation for Science and Technology (FCT), with reference UIDB/50021/2020. Diogo A.P. Nunes is supported by a scholarship granted by FCT, with reference 2021.06759.BD.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Northwestern University gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors